Corona Remedies Ltd. share price target

IPO Note - Corona Remedies Limited Corona Remedies Limited is an India-focused branded pharma firm, develops, manufactures, and markets 71 brands across women's healthcare, cardio-diabeto, pain management, urology, and more

The company has undertaken recent acquisitions like Myoril from Sanofi and Spye from Bayer. It is bolstering its gynaecology and cardiology portfolio and executed a partnership with Ferring for Solifenacin.

formulation company engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. Company is the fastest growing company among the top 30 companies in the Indian Pharmaceutical Market (IPM) in terms of domestic sales in the IPM, between MAT June 2024 and MAT June 2025. During this period, company's domestic sales grew at a CAGR of 13.58% compared to the IPM which grew at a CAGR of...

The company owns installed capacity for wide range of dosage and packaging forms, such as tablets, capsules (including hard and soft gelatines), sachets, liquids and drops, with a total of 11 production lines...

IPO NOTE

Corona Remedies Ltd (Corona) is an India-focused domestic branded formulations company engaged in the development, manufacturing & marketing of products in the women's health, cardio-diabeto, pain management, urology, etc therapies. The company's diversified product portfolio comprises of 71 brands, including 27 engine brands as of Jun'25. On MAT Jun'25 basis, Corona was the 29th largest pharmaceutical company in India and positioned as the 17th largest company in its covered...